

BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN: L24233MP1985PLC002709

Registered Office: B/12-B, Industrial Estate, Pologround, Indore-452015 (M.P.)

Tel. 0731-2426700; Email id- bcplcompliance@gmail.com;

Website- www.biofilgroup.net; Fax: 0731-2426700

Date: 11th August, 2026

To, The Secretary (DCS/Compliance), Corporate Relationship Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001	To, The Secretary (Listing/Compliance), Corporate Relationship Department, National Stock Exchange of India Limited , Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Mumbai – 400051
--	--

Subject: Outcome of Board Meeting held on Tuesday 11th August, 2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Reference: Biofil Chemicals & Pharmaceuticals Limited (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014)

Dear Sir/Madam,

With reference to the above captioned subject and in pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors of the Company in their meeting (Serial No. 02/2026-27) held on today i.e., Tuesday, 11th Day of August, 2026, has inter alia, considered and approved the following businesses:

1. Un-Audited Financial Results of the Company for the quarter ended on 30th June, 2026 along with limited Review Report thereon. **(Copy of financial results enclosed herewith).**
2. Continuation of directorship of Mr. Ashok Kumar Ramawat (DIN: 08818263) as a Non-Executive Independent Director of the Company, upon attaining the age of 75 (seventy-five) years, based on recommendations of Nomination and Remuneration Committee.
3. Approval of Board's Report on the Operation of the Company along with required annexure and Corporate Governance Report & Management Discussion and Analysis Report for the year ended March 31, 2026.
4. Convening of 41st Annual General Meeting (AGM) on Wednesday, 23rd day of September, 2026 at 03.00 P.M. (IST) through Video Conferencing (VC) or Other Audio-Visual Means (OAVM).
5. Other routine businesses with the permission of Chair.

Further, Continuous Disclosure as required pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-PoD2/1/3762/2026 dated 30th January, 2026 as amended from time to time are being submitted separately in pdf and xbrl form with in prescribed time limit.

Furthermore, copy of Un-Audited Financial Results of the Company shall also be submitted in integrated filing financials XBRL within prescribed time limit from the conclusion of Board Meeting.

The aforesaid Un-Audited Financial Results of the Company shall also be uploaded on the Company's website i.e. www.biofilgroup.net and on the website of the Stock Exchanges i.e., at www.bseindia.com and www.nseindia.com. Further, publication containing a Quick Response code and the details of the webpage where complete financial results of the Company are available will be published in Hindi and English Newspapers with in prescribed time limit.

The Meeting of the Board of Directors commenced at 04:30 P.M. and concluded at 05:30 P.M.

The above information will also be available on the website of the Company at www.biofilgroup.net.

You are requested to please take on record the same.

Thanking you.

Yours Faithfully,

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

Apoorv Jain

Digitally signed
by Apoorv Jain
Date: 2026.08.11
18:06:17 +05'30'

**APOORV JAIN
COMPANY SECRETARY & COMPLIANCE OFFICER
M. NO. A71739**


Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To,
The Board of Directors
Biofil Chemicals and Pharmaceuticals Limited
Indore (M.P.)

We have reviewed the accompanying statement of unaudited Standalone Financial results ("the statement") of **Biofil Chemicals and Pharmaceuticals Limited** ("**the company**") for the quarter ended 30th June, 2026 and year to date from 01st April, 2026 to 30th June, 2026 attached herewith. The Statement has been prepared by the Company's Management pursuant to requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 as amended ("the listing regulations").

This statement, which is the responsibility of the Company's management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with rule 3 of Companies (Indian Accounting Standards) Rules, 2015 (as amended), in compliance with Regulation 33 issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "*Review of Interim Financial Information Performed by Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would be




aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard (Ind AS) and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **MAHESHWARI & GUPTA**

Chartered Accountants

FRN: 006179C



CA. SUNIL MAHESHWARI

Partner

M. No. 403346

Place: Indore

Date: 11/08/2026

UDIN: 26403346HUTRDG7531

Statement of Unaudited Financial Results for the quarter ended 30th June 2026

Sr No.	Particulars	Quarter Ended			Previous Year Ended
		June 30, 2026	June 30, 2025	March 31, 2026	March 31, 2026
		Un-Audited	Un-Audited	Audited	Audited
I	Revenue from Operation	1235.02	643.26	756.56	2839.52
II	Other Income	6.26	283.20	10.85	308.23
III	Total Income	1241.28	926.46	767.41	3147.75
IV	Expenses				
	(a) Cost of materials consumed	948.18	117.14	179.84	738.32
	(b) Purchases of stock-in-trade	311.58	974.06	195.43	1876.95
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(81.18)	(497.91)	282.96	(19.19)
	(d) Employee benefits expense	19.36	21.04	22.00	79.98
	(e) Finance Cost	0.07	0.93	0.02	1.01
	(f) Depreciation and Amortisation Expense	6.84	6.60	7.41	27.20
	(g) Other expenses	23.02	28.35	32.87	98.52
	1. Manufacturing Expenses	5.93	5.67	5.59	32.61
	2. Administrative Expenses	16.29	5.85	25.49	60.87
	3. Selling and Distribution Expenses	0.80	16.83	1.79	5.04
	Total expenses	1227.87	650.21	720.53	2802.79
V	Profit/ (Loss) before exceptional items and tax	13.41	276.25	46.88	344.96
VI	Exceptional Items	0.00	0.00	0.00	0.00
VII	Profit/ (Loss) before tax	13.41	276.25	46.88	344.96
VIII	Tax expense:				
	(1) Current tax	2.50	35.15	0.01	40.71
	(2) Deferred tax	0.00	0.00	25.65	25.65
	Total Tax expenses	2.50	35.15	25.66	66.36
IX	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00
X	Profit/(Loss) for the period from continuing operation	10.91	241.10	21.22	278.60
XI	Profit/(Loss) for the period for dis-continued operation	0.00	0.00	0.00	0.00
XII	Tax expenses of discontinued operation	0.00	0.00	0.00	0.00
XIII	Profit/(Loss) for the period for dis-continued operation after tax	0.00	0.00	0.00	0.00
XIV	Profit/ (Loss) for the period	10.91	241.10	21.22	278.60
XV	Other Comprehensive Income				
	A) (I) Items that will not be reclassified to Profit or Loss	0.00	0.00	(0.42)	(0.42)
	(II) Income Tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.10	0.10
	B) (i) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00
	(II) Income Tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00
XVI	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)	10.91	241.10	20.90	278.27
XVII	Paid-Up equity share capital (face value of Rs 10/- each)	1627.38	1627.38	1627.38	1627.38
XVIII	Reserves (Excluding Revaluation Reserve)				152.85
XIX	Earnings per equity shares (for continuing operation):				
	(1) Basic (Rs)	0.07	1.48	0.13	1.71
	(2) Diluted (Rs)	0.07	1.48	0.13	1.71

XX	Earnings Per Equity Share (for discontinued operation)				
	(1) Basic (Rs)	0.00	0.00	0.00	0.00
	(2) Diluted (Rs)	0.00	0.00	0.00	0.00
XXI	Earnings Per Equity Share (for continuing & discontinued operation)				
	(1) Basic (Rs)	0.07	1.48	0.13	1.71
	(2) Diluted (Rs)	0.07	1.48	0.13	1.71

- 1 The above Un-Audited Financial Results for the Quarter ended June 30, 2026 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in it's meeting held on 11th August, 2026. The above results have been reviewed by Statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
- 2 This financial results has been prepared in accordance with the guidelines issued by the Securities Exchange Board of India (SEBI) and Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- 3 The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
- 4 The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments
a. Pharma Product
b. Chemicals Division
- 5 The aforesaid un-audited Financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors. Further, publication containing a Quick Response code and the details of the webpage where complete financial results of the Company are available, will be published in English and Hindi Newspapers with in prescribed time limit.
- 6 The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year and the years to date figures up to the third quarter which were subjected to limited review.
- 7 The increase in revenue from operations for the quarter ended June 30, 2026, as compared to the corresponding quarter ended June 30, 2025, is primarily attributable to an increase in trading activities during the current quarter, resulting in higher sales of traded goods.
- 8 The Company is presently undertaking renovation and upgradation of its manufacturing facility pursuant to the revision in Schedule M of the Drugs and Cosmetics Rules. The said upgradation work is expected to be completed within approximately 3 to 6 months. The Company expects that, upon completion of the upgradation and commencement of regular manufacturing operations, the enhanced manufacturing capabilities will contribute to an improvement in sales in the subsequent periods.

Date : 11th August, 2026
Place : Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED



KETAN SHAH
CHAIRMAN AND MANAGING DIRECTOR
(DIN: 08818212)

Segmentwise Revenue, Results and Capital Employed for quarter ended 30th June-2026

(Amount in Lakhs)

S.No.	Particulars	Quarter Ended			Previous Year Ended
		June 30, 2026	June 30, 2025	March 31, 2026	March 31, 2026
		Un-Audited	Un-Audited	Audited	Audited
1	Segment Revenue				
	Pharma Division	313.40	484.75	111.48	1,896.33
	Chemical Division	921.62	158.51	645.08	943.19
	Net sales/Income From Operations	1,235.02	643.26	756.56	2,839.52
2	Segment Results (Profit)(+)/ Loss (-) before tax and interest				
	Pharma Division	(6.41)	269.74	(30.63)	235.90
	Chemical Division	15.43	7.37	70.15	94.69
	Total Segment Profit Before Tax	9.02	277.11	39.52	330.59
	Interest Income	4.44	0.06	7.34	15.28
	Interest Expenses	0.05	0.92	(0.02)	0.91
	Other Unallocable Income net of Expenditure				
	Profit Before Tax	13.41	276.25	46.88	344.96
3	Capital Employed				
	Segment Assets (A)				
	Pharma Division	2,769.36	3,481.58	2,158.44	2,158.44
	Chemical Division	2,922.96	1,627.23	2,126.37	2,126.37
		5,692.32	5,108.81	4,284.81	4,284.81
	Total (A)				
	Segment Liabilities (B)				
	Pharma Division	1,637.01	2,290.92	1,270.47	1,270.47
	Chemical Division	1,888.31	698.62	857.91	857.91
	Total (B)	3,525.32	2,989.55	2,128.38	2,128.38
4	Total Capital Employed (Segment Assets-Segment Liabilities)				
	Pharma Division	1,132.35	1,190.66	887.97	887.97
	Chemical Division	1,034.65	928.60	1,268.46	1,268.46
	Total Capital Employed (Segment Assets-Segment Liabilities)	2,167.00	2,119.26	2,156.43	2,156.43

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

Date : 11th August, 2026

Place : Indore



KETAN SHAH

CHAIRMAN AND MANAGING DIRECTOR

(DIN: 08818212)